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Statin therapy is associated with improved patency
of autogenous infrainguinal bypass grafts
Thomas A. Abbruzzese, MD,a Joaquim Havens, BS,a Michael Belkin, MD,a Magruder C. Donaldson,
MD,a Anthony D. Whittemore, MD,a James K. Liao, MD,b and Michael S. Conte, MD,a Boston, Mass
Objective: HMG-CoA reductase inhibitors (statins) broadly reduce cardiovascular events, effects that are only partly
related to cholesterol lowering. Recent studies suggest important anti-inflammatory and antiproliferative properties of
these drugs. The purpose of this study was to determine the influence of statin therapy on graft patency after autogenous
infrainguinal arterial reconstructions.
Methods: A retrospective analysis of consecutive patients (1999-2001) who underwent primary autogenous infrainguinal
reconstructions with a single segment of greater saphenous vein was performed. Patients were categorized according to
concurrent use of a statin. Graft lesions (identified by duplex surveillance) and interventions were tabulated. Comparisons
between groups were made by using the Fisher exact test for categorical variables and the Student t test for continuous
variables. Patency, limb salvage, and survival were compared by log rank test. A stepwise Cox proportional hazards
analysis was then employed to ascertain the relative importance of factors influencing graft patency.
Results: A total of 172 patients underwent 189 primary autogenous infrainguinal arterial reconstructions (94 statin, 95
control) during the study period. The groups were well matched for age, indication, and atherosclerotic risk factors.
Procedures were performed primarily for limb salvage (92%), with 65% to an infrapopliteal target. Perioperative mortality
(2.6%) and major morbidity (3.2%) were not different between groups. There was no difference in primary patency (74%
 5% vs 69%  6%; P  .25), limb salvage (92%  3% vs 90%  4%; P  .37), or survival (69%  5% vs 63%  5%; P 
.20) at 2 years. However, patients on statins had higher primary-revised (94% 2% vs 83% 5%; P < .02) and secondary
(97%  2% vs 87%  4%; P < .02) graft patency rates at 2 years. Of all factors studied by univariate analysis, only statin
use was associated with improved secondary patency (P .03) at 2 years. This was confirmed by multivariate analysis. The
risk of graft failure was 3.2-fold higher (95% confidence interval, 1.04-10.04) for the control group. Perioperative
cholesterol levels (available in 47% of patients) were not statistically different between groups.
Conclusions: Statin therapy is associated with improved graft patency after infrainguinal bypass grafting with saphenous
vein. (J Vasc Surg 2004;39:1178-85.)The efficacy and durability of autogenous vein bypass
for the treatment of severe peripheral arterial disease have
been well established.1-3 Despite advances in endovascular
therapies, surgical revascularization remains the mainstay of
treatment, and improving the long-term patency of infrain-
guinal arterial reconstructions is one of the most challeng-
ing problems facing modern vascular surgery. Failure of
vein bypass grafts, which can occur in 30% to 50% of
patients over 5 years, is a common occurrence that directly
results in mortality, limb loss, additional interventions, and
diminished quality of life. Despite more than 2 decades of
investigation, no pharmacologic approach has yet demon-
strated a significant influence on long-term vein graft func-
tion.
The use of 3-hydroxy-3-methylglutaryl-coenzyme A
inhibitors (HMG-CoA reductase inhibitors, or statins) is
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doi:10.1016/j.jvs.2003.12.0271178increasing, as is our knowledge of their beneficial effects in
vascular disease. These cholesterol-lowering agents have
demonstrated salutary effects across the spectrum of cardio-
vascular disease, and a broad range of atheroprotective
properties have been elucidated beyond their effects on
lipid metabolism. Clinical studies have shown that statins
are associated with a reduction in cardiovascular events in
patients with coronary artery disease and have anti-inflam-
matory effects that are independent of their lipid-lowering
effects.4-10 Statins have been shown to prevent new or
worsening symptoms of claudication and were associated
with improved walking distance, walking velocity, and
overall ambulatory performance.11-14 In terms of vessel
wall biology, statins have been demonstrated to improve
endothelial function, reduce smooth muscle cell (SMC)
proliferation and migration, inhibit neointimal inflamma-
tion, reduce plaque SMC and collagen content, and sup-
press the expression of tissue factor and matrix metallopro-
teinases that may influence plaque stability.15-19 Recent
studies have suggested that statin therapy may be associated
with a reduced incidence of graft failure following coronary
artery bypass.20
The purpose of the current study was to determine the
influence of statin therapy on the outcomes of autogenous
vein bypass in lower extremity occlusive disease.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 6 Abbruzzese et al 1179METHODS
We conducted a retrospective review of consecutive
patients who underwent infrainguinal arterial reconstruc-
tions using autogenous saphenous vein at the Brigham and
Women’s Hospital between January 1, 1999 and Decem-
ber 31, 2001. In order to reduce confounding variability in
graft quality and type, only those patients who underwent
primary reconstruction using a single segment of greater
saphenous vein (SSGSV) as a conduit were included in the
study. Data were retrieved from hospital charts (including
medication history); electronic medical records; vascular
laboratory records; clinic records; and a computerized reg-
istry in which patient demographics, risk factor profile,
procedural details, perioperative events, and follow-up in-
formation have been prospectively entered for all vascular
surgery patients at our institution since 1975. Following
chart review, patients were divided into two groups: the
statin group, which consisted of those patients who were
taking a statin at the time of their initial procedure, and the
control group, which consisted of those patients who were
not taking a statin at the time of their operation. Patients
who underwent bilateral procedures during the study pe-
riod were included only if both procedures fell into the
same treatment group (statin or control); in these cases
(n  17), each procedure was treated as an individual data
point in the analysis. Perioperative serum cholesterol levels
were defined as those that were obtained within 3 months
before or after the index procedure.
All operations were performed by a surgical team com-
posed of a staff vascular surgeon and either a vascular fellow
or senior surgical resident using standard techniques of
graft placement and vascular anastomosis that have previ-
ously been described.21,22 Operative reports were reviewed
for indication, graft type, graft orientation, and proximal/
distal anastomotic sites. Postoperative graft surveillance
consisted of duplex ultrasound evaluation of grafts at 1, 3,
6, and 12 months, followed by annual evaluation thereaf-
ter. Surveillance duplex studies were reviewed to assess the
incidence, location, and severity of vein graft lesions. For
patients who had experienced a graft event, only the duplex
evaluation that documented the event or prompted inter-
vention was used in the analysis. For all other patients, we
used the most recent duplex study available for analysis.
Graft lesions were categorized by anatomic location and
severity. Subcritical stenoses were defined by a peak systolic
velocity (PSV) ratio between 2.0 and 3.5 corresponding to
a 50% to 75% reduction in luminal diameter, and critical
stenoses were defined as regions with a velocity ratio greater
than 3.5, or PSV  300 cm/s, corresponding to a 75%
reduction in luminal diameter. Lesions identified by duplex
evaluation were generally confirmed by arteriography in
order to plan subsequent intervention(s).
Minor amputations were defined as those that resulted
in a foot that was still usable for ambulation. Limb salvage
was defined as freedom from major amputation. Primary,
primary-assisted, and secondary patency were defined in
accordance with the suggested reporting standards of theAd Hoc Committee of the Society for Vascular Surgery and
the North American Chapter of the International Society
for Cardiovascular Surgery.23
Survival, graft patency, and limb salvage rates were
calculated with the life-table method, and standard errors
were calculated with the Greenwood method. Compari-
sons between groups were performed by using the Mantel-
Cox log rank analysis. Categorical variables were compared
by using univariate analysis, and individual comparisons
were performed with the Fisher exact test. Continuous
variables were compared with a two-tailed Student t test. A
stepwise Cox proportional hazards analysis was then em-
ployed to ascertain the relative importance of factors influ-
encing graft patency. The dependent variable in this analy-
sis was time to occlusion. In all comparisons, a P value of
.05 was considered the threshold for statistical signifi-
cance. Loss to follow-up was defined as no patient contact
for more than 18 months.
RESULTS
Characterization of study cohort. During the study
period, a total of 176 patients underwent 197 primary
infrainguinal arterial reconstructions using SSGSV. A total
of 21 patients underwent bilateral procedures during the
study interval that met the inclusion criteria; however, 4
patients were excluded because they crossed over between
the statin and control groups between operations. This
resulted in a total of 172 patients and 189 grafts available
for analysis (88 patients and 94 grafts in the statin group, 84
patients and 95 grafts in the control group). Follow-up was
complete in 87% of patients, with a mean of 525 (range,
1-1,474) days. This was not significantly different between
groups (statin group 543 days, control group 507 days).
Table I lists the demographic and risk factor profiles for
the study patients. There was a greater prevalence of coro-
nary artery disease and history of coronary artery bypass
grafting in the statin group than in the control group.
There was no difference between groups in gender, diabe-
tes, smoking, hypertension, congestive heart failure, arryth-
mia, cerebrovascular disease, chronic pulmonary disease, or
chronic renal disease.
Perioperative cholesterol levels were available for anal-
ysis in 47% of patients. The mean cholesterol level was 170
 60 mg/dL and was not significantly different between
groups. Statin drugs used included atorvastatin (30%), cer-
ivastatin (1%), lovastatin (3%), pravastatin (2%), and simva-
statin (64%).
Overall, 90% of study patients were taking some form of
antithrombotic agent, including aspirin (63%), warfarin
sodium (6%), clopidogrel (1.7%), pentoxifylline (1.3%), or
some combination of these (18%). There was no difference
in the incidence or type of antithrombotic agent use be-
tween groups.
Overall, 179 of 189 (95%) operations performed on
patients during the study interval were performed by three
staff vascular surgeons. There was an equal distribution
among surgeons in both the number and type of procedure
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assigned (statin vs control).
Forty-six percent of the operations were performed
under general anesthesia alone, and 54% were performed
with a combination of regional and general anesthetic
techniques. There was no difference in the anesthetic
method used between groups.
Table II summarizes the operative indications and graft
characteristics of all procedures in the study. Of the 172
procedures, 8% were for claudication and 92% were for limb
salvage, of which 24% were for rest pain and 68% for tissue
loss. The proximal anastomosis arose from the common
femoral artery (CFA) in 53%, the superficial femoral artery
(SFA) in 25%, and the popliteal artery in 22% of cases.
Grafts more commonly arose from the SFA in the control
group than in the statin group (P  .03). The distal
anastomosis was created in the above-knee popliteal artery
in 12%, the below-knee popliteal artery in 22%, the tibio-
peroneal trunk in 0.5%, the anterior tibial artery in 16%, the
posterior tibial artery in 21%, the peroneal artery in 13%,
and the dorsalis pedis artery in 15%. Graft orientation
consisted of 32% in situ, 52% nonreversed, and 16% re-
versed saphenous vein grafts. There was no difference in
operative indication, distal anastomotic site, or graft orien-
tation between groups.
Perioperative events. Postoperative (30-day) mortal-
ity and morbidity are summarized in Table III. Thirty-day
operative mortality occurred in 5 patients (2.6%)—3 from
multisystem failure, 1 from lung cancer, and 2 from un-
known cause—and was not significantly different between
groups (2 deaths in the statin group, 3 deaths in the control
group; P  .51). The overall postoperative morbidity rate
was 21%, and was not significantly different between
Table I. Patient demographic and risk factor profiles*
Characteristic Overall
Limbs treated 189
Men/women 101/71
Age (y) 69  10
Diabetes 104
Smoking 35
Hypertension 114
Coronary artery disease 94
Prior coronary artery bypass grafting 42
Congestive heart failure 26
Arrythmia/atrial fibrillation 24
Cerebrovascular disease 27
Chronic pulmonary disease 16
Chronic renal disease 49
Hemodialysis-dependent 31
Perioperative total cholesterol (mg/dL) 170  60 (n  80
Statin type (n  88)
Atorvastatin
Cerivastatin
Lovastatin
Pravastatin
Simvastain
*Data shown as either coded raw data (n) or summary data (mean  SD).groups. Early graft thrombosis (30 days) occurred in
3.7% of grafts and was not significantly different between
groups (P  .06).
Long-term outcomes. Overall 2-year cumulative pa-
tient survival was 66%  4% and was not significantly
different between groups (statin group 69%  5%, control
group 63%  5%; P  .20). Table IV, and Figs 1 and 2
depict the primary, primary-revised, and secondary patency
rates and limb salvage rates for the entire patient cohort.
Combined primary patency at 2 years was 72%  4% and
was not significantly different between groups (statin group
74%  5%, control group 69%  6%; P  .25). Two-year
primary-revised patency was 89% 3% (statin group 94%
2%, control group 83%  5%; P  .02), and secondary
patency was 92%  2% (statin group 97%  2%, control
group 87%  4%; P  .02). Both primary-revised and
secondary patencies were significantly greater in the statin
group. The overall risk of graft failure was 3.2-fold higher
(95% confidence interval, 1.04-10.04) for the control
group. Limb salvage at 2 years was 91%  3% and was not
significantly different between groups.
By univariate analysis, only statin use (P  .03) had a
significant association with secondary graft patency
among the risk factors analyzed (smoking, diabetes,
hypertension, coronary artery disease, history of coro-
nary artery bypass grafting, chronic obstructive pulmo-
nary disease, chronic renal disease, proximal or distal
anastomotic sites). When all variables were examined in a
stepwise Cox proportional hazards model, the associa-
tion with statins alone remained significant (P  .03).
Although the groups were not well matched for hemo-
dialysis dependence, there was no observable impact of
renal disease on graft patency in this series. Four dialysis
Group
PStatin Control
94 95
54/34 47/37 .47
67  10 70  11 .04
58 46 .14
17 18 .73
54 60 .16
59 35 .01
28 14 .02
13 13 .90
10 14 .27
13 14 .73
8 8 .92
20 29 .09
11 20 .05
174  66 (n  38) 168  54 (n  42) .67
28 (30%)
1 (1%)
3 (3%)
2 (2%)
60 (64%))
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that maintained patency and only two permanent graft
failures occurred in patients with chronic renal disease,
both of whom were not hemodialysis-dependent. Con-
sistent with other series, a reduced survival of the dialy-
sis-dependent cohort (29%  9% at 2 years) was ob-
served, thereby limiting the potential effect of this
comorbidity on long-term graft function. Nonetheless,
even when hemodialysis patients are excluded from the
analysis, there remains a statistically significant improve-
ment in secondary patency at 2 years associated with
statin use (statin group 94%  3% vs control group 81%
 5%, P  .02).
Characterization of graft lesions, events, and inter-
ventions. Postoperative duplex examinations were avail-
able for analysis in 146 of 189 grafts (77%). The incidence
and type of graft lesions, events, and subsequent interven-
tions are summarized in Table V. Of the 189 grafts in-
cluded in the study, 64 (34%) had no significant lesions on
the last available duplex examination, 23 (12%) developed
subcritical lesions, 38 (20%) developed critical lesions, 21
(11%) occluded, and 43 (23%) had no duplex examination
available for evaluation. Of the 61 grafts that developed a
significant, nonoccluding lesion, 7 (11%) occurred in the
inflow vessel, 22 (36%) occurred at the proximal or distal
anastomosis, 17 (28%) occurred within the graft, 6 (10%)
occurred in the outflow vessel, and 9 (15%) developed
stenoses in multiple sites. There was no difference in either
the location or severity of stenoses between groups. Four
study patients, one in the statin group and three in the
control group, had critical stenoses identified by duplex
examination that did not lead to an intervention. Of these
patients, two died (one statin patient, one control patient)
with a patent graft and two patients continue under clinical
observation.
The mean time to intervention was 230  228 days
with a median of 176 days and was not significantly differ-
Table II. Operative indications and graft characteristics*
Characteristic
Group
POverall Statin Control
Operative indication
Claudication 16 10 6 .29
Limb salvage (combined) 173 84 89 .29
Rest pain 44 22 22 .97
Tissue loss 129 62 67 .50
Proximal anastomotic site
Common femoral artery 101 55 46 .16
Superficial femoral artery 47 17 30 .03
Popliteal artery 41 22 19 .57
Distal anastomotic site
Popliteal artery 65 36 29 .26
Tibial/pedal arteries 124 58 66 .26
Graft orientation
In situ saphenous vein 61 33 28 .41
Non-reversed saphenous vein 98 45 53 .28
Reversed saphenous vein 30 16 14 .67
*Data shown as coded raw data (n).ent between groups. Of the 42 interventions performed on
study patients, there were 4 (10%) thrombolysis/throm-
bectomies, 10 (24%) angioplasties (1 percutaneous, 9
open), 13 (31%) interposition and jump grafts, 3 (7%)
combination procedures, 3 (7%) occluded grafts that re-
sulted in major amputations, and 9 (21%) new grafts con-
structed to replace occluded grafts. There was no signifi-
cant difference in the incidence or type of interventions
performed between groups.
Twenty-one grafts developed occlusion during the
study interval. Six grafts occluded within the first postop-
erative week, only one of which was salvaged by thrombec-
tomy. Thirteen grafts presented occluded without prior
duplex evidence of graft stenosis, and two grafts had pre-
occlusive lesions identified on duplex surveillance prior to
the occlusion event. In these two patients, the time be-
tween lesion identification and graft occlusion was 3 and 11
months respectively.
Table III. Postoperative mortality and morbidity*
Characteristic
Group
P
Overall
(%) Statin Control
30-day mortality 5 (2.6) 2 3 .51
Overall morbidity 40 (21) 15 25 .08
Major morbidity 6 (3.2) 3 3 .65
Myocardial infarction 3 (1.6) 2 1 .55
Stroke 0 (0) 0 0 N/A
Renal failure 2 (1.1) 0 2 .25
Pulmonary complications 1 (0.5) 1 0 .50
Other morbidities
Early graft thrombosis 7 (3.7) 1 6 .06
Early amputation 1 (0.5) 0 1 .32
Cardiovascular (other)
Congestive heart failure 3 (1.6) 2 1 .50
Arrythmia 7 (3.7) 3 4 .51
Gastrointestinal
Cholecystitis 2 (1) 0 2 .25
Ischemic colitis 2 (1) 0 2 .25
Pancreatitis 1 (0.5) 0 1 .32
Deep venous thrombosis 1 (0.5) 1 0 .50
Wound infection 15 (6.8) 5 10 .15
Hematoma/seroma 3 (1.6) 1 2 .50
*All events occurred within 30 days of surgery.
Data shown as coded raw data (n) and percent.
Table IV. Two-year outcomes of survival, primary-
revised, and secondary patencies and limb salvage*
Characteristic
Group
POverall Statin Control
Survival 66  4 69  5 63  5 .20
Primary patency 72  4 74  5 69  6 .25
Primary-revised patency 89  3 94  2 83  5 .02
Secondary patency 92  2 97  2 87  4 .02
Limb salvage 91  3 92  3 90  4 .37
*All data shown as percent  SE of the mean.
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Our results suggest that statin therapy may have a
beneficial effect on the patency of autogenous infrainguinal
bypass grafts. The observed difference in outcomes was
almost exclusively related to a lower incidence of graft
occlusions in the statin group and a correspondingly
greater number of unsalvageable grafts in the control
group. Primary patency rates were not different, nor were
there any significant differences in the incidence or severity
of occult graft stenoses identified on duplex surveillance.
This retrospective study has significant limitations and
its findings should be interpreted with some caution. First,
data on statin use was obtained retrospectively from patient
records and may be incomplete; thus we are unable to
determine patient compliance or duration of therapy. Avail-
able data on serum cholesterol was also limited to approx-
imately half of the cohort, limiting the power to analyze the
influence of this variable. The two groups identified from
this consecutive cohort of primary bypasses were relatively
well matched in number and risk factor prevalence, and
multivariate analysis did not demonstrate an association
between any of the other variables tested and graft patency.
Nonetheless, the relatively small sample size limits the
statistical power for analysis of potentially confounding
Fig 1. Cumulative primary patency ovariables. The apparent beneficial influence of statins (3.2-
fold risk reduction) was statistically significant, but the wide
confidence interval demonstrates the limited robustness of
a small series. A multicenter, prospective randomized trial
to examine the question appears to be indicated but may be
difficult to execute due to the increasing prevalence of
statin use and potential concerns with removing patients
from therapy prior to randomization. Despite the limita-
tions noted, when taken in the context of the available
evidence on statins and peripheral arterial disease, this
report adds further rationale to support a broader use of
these agents in advanced limb ischemia patients.
The potential mechanisms by which statins may influ-
ence vein graft disease remain speculative. Statins have been
shown to have a variety of anti-inflammatory and antiath-
erosclerotic properties, and several large clinical series have
established that statins reduce the risk of coronary
events24,25 and stroke.6,24-27 Many studies have also dem-
onstrated a predictive association between serum concen-
trations of C-reactive protein (CRP), an acute-phase reac-
tant, and the long-term risk of cardiovascular events.28-30
Even in healthy, symptomless adults, a single CRP level in
the high normal range predicts an increased long-term risk
of cardiovascular events including angina pectoris, myocar-
statin and control groups (P  .25).
Fig 2. Cumulative secondary patency of the statin and control groups (P  .02).
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Characteristic
Group
P
Overall
(%) Statin Control
Graft disease burden
No significant disease 64 (34) 33 31 .72
Subcritical stenosis 23 (12) 12 11 .80
Critical stenosis 38 (20) 24 14 .06
Occlusion 21 (11) 7 14 .11
Unknown 43 (23) 18 25 .24
Clinical events
Overall 49 (100) 22 27 .43
Elective revision 28 (57) 15 13 .66
Graft occlusion 21 (43) 7 14 .11
Interventions
Overall 42 (100) 20 22 .76
Thrombolysis/Thrombectomy 4 (10) 1 3 .32
Angioplasty 10 (25) 7 3 .19
Interposition/Jump graft 13 (31) 6 7 .79
Combination/Multiple 3 (7) 2 1 .55
Amputation 3 (7) 2 1 .55
New graft constructed 9 (21) 2 7 .09
Time to intervention (days)
Mean 230  228 225  203 234  251 .90
Median 176 182 152
*Data shown as either coded raw data (n) with percent or summary data (mean  SD).
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decrease the serum concentration of CRP in a manner
independent of serum lipid concentration reduction.31,32
Basic investigations have demonstrated a significant inflam-
matory response in the vein graft wall33-36; however, to
date there is limited clinical evidence directly linking in-
flammation with graft disease or failure.37 This is a subject
of ongoing studies.
Recent studies have provided insight into the mecha-
nisms by which statins exert their beneficial effects on
inflammation and atherogenesis. Statins inhibit lipopoly-
saccharide-stimulated production of inflammatory cyto-
kines (eg, tumor necrosis factor– and interleukin-6) by
leukocytes,38,39 and inhibit T cell activation and antigen-
presenting functions.40,41 An in vivo study demonstrated a
significant reduction in inflammation in a mouse model
with a 1 hour predose of simvastatin to a degree that was
comparable to indomethacin.10 The same study demon-
strated a reduction in atherosclerosis in apolipoprotein
E-deficient mice after 6 weeks of simvastatin administra-
tion—an effect independent of cholesterol lowering. A
clinical study of patients with familial hypercholesterolemia
demonstrated a significant reduction in carotid and femoral
artery intima-media thickness after 2 years of treatment
with simvastatin.42 In studies of intimal hyperplasia, statins
have been shown to inhibit smooth muscle proliferation
and migration,43,44 stimulate SMC apoptosis,45 and possi-
bly affect monocyte recruitment by inhibiting expression of
monocyte chemotactic protein-1.46 These studies provide
strong evidence for the anti-inflammatory and antiathero-
genic properties of the statin agents.
Statins have potent, beneficial effects on endothelial
function that are directly relevant to the vascular injury
response. Statins inhibit Rho/Rho-kinase activity, thereby
leading to an increase in the expression and activity of
endothelial nitric oxide synthase (eNOS).47,48 Statins have
been shown to inhibit ischemic strokes in normal mice, but
not in eNOS-deficient mice.49 Recent studies have demon-
strated that statins increase the number and differentiation
of circulating endothelial progenitor cells,50-52 which may
be involved in local re-endothelialization at sites of injury
(eg, vein graft). Finally, there is also evidence of a positive
effect of statins on the endothelial-based fibrinolytic system
by a reduction in the level of plasminogen activator inhib-
itor type-1 and increase in the levels of tissue plasminogen
activator, suggesting a potential mechanism for antithrom-
botic effects.53-55
In the present study, an improvement in secondary
patency without a reduction in occult stenoses was demon-
strated in the statin group. This leads us to speculate that
statins may have either reduced the overall virulence of the
graft hyperplasia response, or perhaps exerted a primary
antithrombotic effect. Further studies are clearly indicated
to confirm the validity of these clinical findings and to
examine the mechanisms by which statins may influence
vein graft disease.The authors would like to thank Ms. Julie Lombara for
her assistance in maintenance of the vascular registry, data
retrieval, and statistical analysis. Peter Gaccione, MA (De-
partment of Health Care Policy, Harvard Medical School)
provided biostatistical consultation and performed the
multivariate analysis.
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